Presumed moxidectin toxicosis in three foals.

This study describes the complications and outcomes of administering moxidectin gel to foals less than 4 months old, highlighting the risks of overdose due to horse owners’ lack of comprehension of the drug dosage instructions.

Study Overview

• This study investigates the effects of moxidectin gel administration on three foals that are less than 4 months old. The main focus is to understand the complications and outcomes connected to the usage of this drug.

Findings

• The researchers observed that two of the foals became comatose after being treated with the gel. However, they survived after receiving supportive treatments. The third foal, unfortunately, passed away after losing consciousness, which was linked to the administration of the drug.

Implication of the findings: Risk of Moxidectin Overdose

• The research also underscores the risk of overdose associated with the use of moxidectin. Researchers noted that this may be due to the failure of horse owners to understand or read the instructions pertaining to drug dosage.

Further findings and recommendations

• The study states that moxidectin should not be administered to foals that are younger than 4 months. This recommendation is based on the observation that treated foals tend to become comatose. As such, the researchers warn of a high likelihood of adverse effects, such as coma, if the drug is used on very young foals.

Conclusion

• In conclusion, this research highlights the risks involved in using moxidectin gel on foals younger than 4 months old. It underscores the importance of correctly reading and understanding dosage instructions to mitigate the risk of potential overdose.